Literature DB >> 26659474

An Update on Medical Treatment Options for Hidradenitis Suppurativa.

I E Deckers1, E P Prens2.   

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent inflammatory nodules mostly located in the armpits and groin. Over the years multiple treatments for HS have been proposed; however, to date a cure is still lacking. In this update we provide an overview of most drug treatments reported on for HS, where possible with their mode of action and side effects. In mild cases, clindamycin lotion or resorcinol cream have proven effective. Tetracyclines are a first-line systemic option in more widespread or severe cases, followed by the combination of clindamycin and rifampicin. However, the recurrence rate is high after discontinuation of clindamycin plus rifampicin combination therapy. Long-term treatment with retinoids, especially acitretin is feasible, although teratogenicity has to be taken into account in females of reproductive age. Multiple anti-inflammatory drugs have been suggested for HS, such as dapsone, fumarates or cyclosporine. However, their effectiveness in HS is based on small case series with varying results. If most common treatments have failed, biologics (e.g., infliximab or adalimumab) are the next step. Although not addressed in this review, surgical interventions are often needed to achieve remission.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26659474     DOI: 10.1007/s40265-015-0516-5

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  140 in total

1.  Clindamycin and rifampicin combination therapy for hidradenitis suppurativa.

Authors:  C O Mendonça; C E M Griffiths
Journal:  Br J Dermatol       Date:  2006-05       Impact factor: 9.302

Review 2.  Colchicine in clinical medicine. A guide for internists.

Authors:  Giuseppe Cocco; David C C Chu; Stefano Pandolfi
Journal:  Eur J Intern Med       Date:  2010-11-05       Impact factor: 4.487

3.  Azathioprine lacks efficacy in hidradenitis suppurativa: a retrospective study of nine patients.

Authors:  M Nazary; E P Prens; J Boer
Journal:  Br J Dermatol       Date:  2015-11-03       Impact factor: 9.302

Review 4.  The use of cyclosporine in dermatology: part I.

Authors:  Karrie T Amor; Caitriona Ryan; Alan Menter
Journal:  J Am Acad Dermatol       Date:  2010-12       Impact factor: 11.527

Review 5.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

6.  A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.

Authors:  I Miller; C D Lynggaard; S Lophaven; C Zachariae; D N Dufour; G B E Jemec
Journal:  Br J Dermatol       Date:  2011-06-30       Impact factor: 9.302

7.  Immunomodulating activity of rifampicin.

Authors:  H M Ziglam; I Daniels; R G Finch
Journal:  J Chemother       Date:  2004-08       Impact factor: 1.714

8.  Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.

Authors:  Alexa B Kimball; Francisco Kerdel; David Adams; Ulrich Mrowietz; Joel M Gelfand; Robert Gniadecki; Errol P Prens; Joel Schlessinger; Christos C Zouboulis; Hessel H van der Zee; Marie Rosenfeld; Parvez Mulani; Yihua Gu; Susan Paulson; Martin Okun; Gregor B E Jemec
Journal:  Ann Intern Med       Date:  2012-12-18       Impact factor: 25.391

9.  Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity.

Authors:  Florence Canoui-Poitrine; Jean E Revuz; Pierre Wolkenstein; Cédric Viallette; Germaine Gabison; Florence Pouget; Florence Poli; Ousmane Faye; Sylvie Bastuji-Garin
Journal:  J Am Acad Dermatol       Date:  2009-04-29       Impact factor: 11.527

10.  Antimicrobial agents induce monocytes to release IL-1 alpha, IL-6, and TNF, and induce lymphocytes to release IL-4 and TNF tau.

Authors:  M A Tufano; G Cipollaro de l'Ero; R Ianniello; A Baroni; F Galdiero
Journal:  Immunopharmacol Immunotoxicol       Date:  1992       Impact factor: 2.730

View more
  10 in total

1.  An Atypical Localized Form of Hidradenitis Suppurativa of the Jawline and Neck Mimicking Severe Cystic Acne on Presentation.

Authors:  María Adriana Castrillón Velásquez; Minhee Kim; Mei-Heng Tan; Kim Tran; Dedee F Murrell
Journal:  Skin Appendage Disord       Date:  2017-06-14

Review 2.  The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.

Authors:  Ahmed Shah; Raed Alhusayen; Saeid Amini-Nik
Journal:  Inflamm Res       Date:  2017-06-27       Impact factor: 4.575

3.  Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology.

Authors:  Ayman Grada; Mahmoud A Ghannoum; Christopher G Bunick
Journal:  Antibiotics (Basel)       Date:  2022-05-27

Review 4.  IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa.

Authors:  J M Fletcher; B Moran; A Petrasca; C M Smith
Journal:  Clin Exp Immunol       Date:  2020-06-08       Impact factor: 4.330

5.  Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?

Authors:  Tasnim Abdalla; Michelle A Lowes; Nirmal Kaur; Robert G Micheletti; A Hillary Steinhart; Afsaneh Alavi
Journal:  Am J Clin Dermatol       Date:  2021-03       Impact factor: 6.233

6.  Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice.

Authors:  Errol P Prens; Aida M Lugo-Somolinos; Amy S Paller; Francisco Kerdel; Yinghui Duan; Henrique D Teixeira; Michelle Longcore; Alexa B Kimball
Journal:  Am J Clin Dermatol       Date:  2020-08       Impact factor: 7.403

Review 7.  Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms.

Authors:  John W Frew; Jason E Hawkes; James G Krueger
Journal:  Ther Adv Chronic Dis       Date:  2019-03-01       Impact factor: 5.091

Review 8.  A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders.

Authors:  Ji-Eun Chang; Min Sik Choi
Journal:  Int J Mol Sci       Date:  2020-11-25       Impact factor: 5.923

Review 9.  Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.

Authors:  Zuzanna Świerczewska; Miłosz Lewandowski; Agnieszka Surowiecka; Wioletta Barańska-Rybak
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

10.  The Clinical Pattern of Axillary Hidradenitis Suppurativa among Saudi Arabians: Mode of Presentation and Treatment Challenges.

Authors:  Bader Hamza Shirah; Hamza Asaad Shirah
Journal:  J Cutan Aesthet Surg       Date:  2017 Apr-Jun
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.